公开(公告)号：US20230277695A1

公开(公告)日：2023-09-07

申请号：US18046881

申请日：2022-10-14

Applicant: CALIFORNIA INSTITUTE OF TECHNOLOGY

Inventor： Anupama LAKSHMANAN ,  Arash FARHADI ,  Suchita P. NETY ,  Raymond W. BOURDEAU ,  Mikhail SHAPIRO

IPC: A61K49/22 ,  A61B8/08 ,  C07K14/195 ,  A61K49/00

CPC classification number: A61K49/223 ,  A61B8/481 ,  A61K49/0002 ,  A61K49/0045 ,  A61K49/0093 ,  A61K49/221 ,  C07K14/195 ,  A61B8/5238 ,  C07K2319/00

Abstract: Gas vesicles, protein variants and related compositions methods and systems for singleplexed and/or multiplexed ultrasound imaging of a target site in which a gas vesicle provides contrast for the imaging which is modifiable by application of a selectable acoustic collapse pressure value of the gas vesicle.

公开(公告)号：US20230248827A1

公开(公告)日：2023-08-10

申请号：US18012237

申请日：2021-06-25

Applicant: Pharma Development Holding GmbH

Inventor： Wolfgang Greb

IPC: A61K41/00 ,  A61K49/00 ,  A61K9/127 ,  A61K45/06 ,  A61K47/54

CPC classification number: A61K41/0028 ,  A61K49/0002 ,  A61K9/1271 ,  A61K45/06 ,  A61K47/548 ,  A61K47/542 ,  A61K47/554

Abstract: The invention relates to liposomes containing nanoparticles, wherein the nanoparticles are selected from magnetic, zparamagnetic, superparamagnetic and/or fluorescent and/or functionalized nanoparticles, and the liposomal sleeve contains lipid-derivatized bisphosphonic acid. The liposomes are suitable for preparing a solution for the diagnosis of pathological tissue degeneration or conversion processes on the bone and in the bone marrow, in particular for the treatment and diagnosis of bone tumors and bone metastases and disorders in the bone marrow (proliferative diseases of the blood-producing and lymphoreticular system).

公开(公告)号：US20230218783A1

公开(公告)日：2023-07-13

申请号：US17212878

申请日：2021-03-25

Applicant: Cardinal Health 414, LLC

Inventor： Frederick O. COPE

IPC: A61K51/06 ,  A61K51/10 ,  A61K49/00 ,  A61K51/04 ,  A61K31/655 ,  A61K31/704 ,  A61K47/61

CPC classification number: A61K51/065 ,  A61K31/655 ,  A61K31/704 ,  A61K47/61 ,  A61K49/0002 ,  A61K49/0032 ,  A61K49/0041 ,  A61K49/0052 ,  A61K49/0054 ,  A61K51/0478 ,  A61K51/0491 ,  A61K51/1018 ,  A61K51/1027 ,  A61K51/1096 ,  Y02A50/30

Abstract: Provided are compounds and compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells and methods of treatment and diagnosis using such compounds and compositions.

公开(公告)号：US20230190953A1

公开(公告)日：2023-06-22

申请号：US18054065

申请日：2022-11-09

Applicant: FUNDACIÓN INSTITUTO DE INVESTIGACIÓN SANITARIA DE SANTIAGO DE COMPOSTELA (FIDIS) ,  SERVIZO GALEGO DE SAÚDE

Inventor： María DE LA FUENTE FREIRE ,  Rafael LÓPEZ LÓPEZ ,  Belén LÓPEZ BOUZO ,  Abi Judit VÁZQUEZ RÍOS ,  Marta ALONSO NOCELO

IPC: A61K47/69 ,  A61K47/64 ,  A61K47/54 ,  A61P35/00 ,  A61K9/107 ,  A61K31/05 ,  A61K31/12 ,  A61K31/337 ,  A61K31/513 ,  A61K31/685 ,  A61K31/7048 ,  A61K31/7068 ,  A61K41/00 ,  A61K45/06 ,  A61K47/10 ,  A61K47/22 ,  A61K47/24 ,  A61K49/00 ,  A61K51/12

CPC classification number: A61K47/6907 ,  A61K47/6425 ,  A61K47/64 ,  A61K47/549 ,  A61P35/00 ,  A61K9/1075 ,  A61K31/05 ,  A61K31/12 ,  A61K31/337 ,  A61K31/513 ,  A61K31/685 ,  A61K31/7048 ,  A61K31/7068 ,  A61K41/0071 ,  A61K45/06 ,  A61K47/10 ,  A61K47/22 ,  A61K47/24 ,  A61K49/0002 ,  A61K49/0078 ,  A61K51/122

Abstract: Various oil-in-water (O/W) nanoemulsions containing an oil phase or oil core, preferably selected from vitamin E or oleic acid, stabilized by a sphingolipid of the sphingomyelin type, and optionally other lipids such as phospholipids, cholesterol, octadecylamine, DOTAP (N-[1-(2,3-Dioleoyloxy) propyl]-N, N, N-trimethylammonium methyl-sulfate), and PEGylated derivatives (derivatives with polyethylene glycol), for use as a nanotech vehicle, for example for the management of cancer and metastatic disease. Said nanoemulsions can be functionalized with ligands capable of interacting or binding to receptors expressed on the cell membrane of tumor cells, and in particular capable of interacting or binding to receptors expressed on the membrane of primary and/or disseminated or metastatic tumor cells. Also, antitumor drugs or therapeutic biomolecules can be encapsulated in said nanoemulsions and, finally, contrast agents can be incorporated for their use in the in vivo diagnosis in said nanoemulsions.

公开(公告)号：US20230190656A1

公开(公告)日：2023-06-22

申请号：US18096869

申请日：2023-01-13

Applicant: The Johns Hopkins University

Inventor： Samuel K. Lai ,  Ming Yang ,  Ying-Ying Wang ,  Olcay Mert ,  Laura Ensign ,  Justin Hanes ,  Jie Fu

IPC: A61K9/16 ,  A61K47/69 ,  A61K47/60 ,  A61K9/51 ,  A61K45/06 ,  A61K9/00 ,  A61K31/355 ,  A61K49/00

CPC classification number: A61K9/1641 ,  A61K47/6935 ,  A61K47/60 ,  A61K9/5146 ,  A61K45/06 ,  A61K9/0034 ,  A61K31/355 ,  A61K49/0002 ,  Y10T428/2998

Abstract: The present invention generally relates to reducing the mucoadhesive properties of a particle. In some embodiments, the particle is coated with and/or associated with a (poly(ethylene glycol))-(poly(propylene oxide))-(poly(ethylene glycol)) triblock copolymer. Methods for preparing inventive particles using a poly(ethylene glycol)-vitamin E conjugate as a surfactant are also provided. In some embodiments, methods are provided comprising administering to a subject a composition of particles of the present invention. Such particles with reduced mucoadhesive properties are useful in delivering agents to mucosal tissues such as oral, ophthalmic, gastrointestinal, nasal, respiratory, and genital mucosal tissues.

公开(公告)号：US11648556B2

公开(公告)日：2023-05-16

申请号：US17061247

申请日：2020-10-01

Applicant: The University of British Columbia

Inventor： Pieter R. Cullis ,  Igor V. Jigaltsev ,  Robert James Taylor ,  Timothy Leaver ,  Andre Wild ,  Nathan Maurice Belliveau

IPC: A61F13/00 ,  B01L3/00 ,  A61K9/107 ,  A61K9/127 ,  B01F23/41 ,  B01F25/431 ,  B01F25/433 ,  B01F33/30 ,  A61K9/14 ,  A61K31/704 ,  A61K47/44 ,  A61K49/00 ,  A61J3/00

CPC classification number: B01L3/50273 ,  A61J3/00 ,  A61K9/1075 ,  A61K9/127 ,  A61K9/1271 ,  A61K9/1277 ,  A61K9/14 ,  A61K31/704 ,  A61K47/44 ,  A61K49/0002 ,  B01F23/41 ,  B01F25/431 ,  B01F25/4331 ,  B01F33/30 ,  B01L3/502715 ,  B01F25/431971 ,  B01L2200/0605 ,  B01L2200/0647 ,  B01L2300/06 ,  B01L2300/0848 ,  B01L2300/0867 ,  B01L2300/18 ,  Y10T428/2982

Abstract: Limit size lipid nanoparticles, methods for using the lipid nanoparticles, and methods and systems for making limit size lipid nanoparticles.

公开(公告)号：US20190211063A1

公开(公告)日：2019-07-11

申请号：US16231738

申请日：2018-12-24

Applicant: The Administrators of the Tulane Educational Fund ,  The Johns Hopkins University

Inventor： William C. WIMLEY ,  Gregory WIEDMAN ,  Kalina HRISTOVA ,  Sarah Y. KIM

IPC: C07K14/00 ,  A61K9/127 ,  A61P35/00 ,  A61K49/00

CPC classification number: C07K14/001 ,  A61K9/1271 ,  A61K49/0002 ,  A61P35/00

Abstract: Described herein are membrane permeabilizing peptides, polynucelotides encoding the peptides, and lipid vesicles comprising the peptides. Furthermore, described herein are methods for using the peptides, polynucleotides, and lipid vesicles for research, diagnosis, disease prevention, and therapeutic treatment.

公开(公告)号：US20180333506A1

公开(公告)日：2018-11-22

申请号：US15981568

申请日：2018-05-16

Applicant: Northwestern University

Inventor： Ming Zhao ,  Steven E. Johnson

IPC: A61K49/00 ,  A61K51/04

CPC classification number: A61K49/0002 ,  A61K49/06 ,  A61K51/0474 ,  A61K2123/00 ,  G01N33/5091 ,  G01N2510/00

Abstract: Provided herein are compositions, systems, and methods for minimally-invasive assessment of toxicity-induced tissue injury. In particular, external (e.g., whole-body) scanning is employed to detect toxicity-induced injuries, such as those caused by chemotherapeutics.

公开(公告)号：US20180280546A1

公开(公告)日：2018-10-04

申请号：US15471719

申请日：2017-03-28

Applicant: Asahi TOMITAKA ,  Madhavan NAIR

Inventor： Asahi TOMITAKA ,  Madhavan NAIR

IPC: A61K49/18

CPC classification number: A61K49/0002 ,  A61K9/0019 ,  A61K9/127 ,  A61K41/00 ,  A61K47/6923 ,  A61K47/6929 ,  A61K49/0065 ,  A61K49/0093 ,  A61K49/0423 ,  A61K49/183

Abstract: Materials and methods for synthesizing magnetic core/gold shell nanoparticles and magneto-plasmonic nanostars are provided. Formulations comprising nanoparticles optionally bound to or co-loaded with a therapeutic agent encapsulated within liposomes are provided. A method for treating diseases (e.g., brain diseases) in a subject by administering to the subject a formulation comprising the nanoparticle formulation is also provided. Further, a method is provided for imaging a target site of a subject following the administering of the nanoparticle formulations.

公开(公告)号：US10081653B2

公开(公告)日：2018-09-25

申请号：US15214675

申请日：2016-07-20

Applicant: Institute of Nuclear Energy Research, Atomic Energy Council, Executive Yuan, R.O.C.

Inventor： Rui-Yu Chen ,  Yan-Feng Jiang ,  Mei-Hui Wang ,  Jen-Tsung Wang ,  Wuu-Jyh Lin

IPC: C07H15/26 ,  A61K49/00 ,  C07H1/00

CPC classification number: C07H15/26 ,  A61K49/0002 ,  C07H1/00

Abstract: The present invention provides a method for preparing a 6-aminohexyl lactoside-NOTA conjugate. The preparation method comprises brominating perbenzoylated lactose with hydrobromic acid; glycosylating 6-azidohexanol to obtain 6-azidohexyl perbenzoyl lactoside; and deprotecting this precursor in two steps to obtain 6-aminohexyl lactoside and conjugating 6-aminohexyl lactoside to NCS-benzyl-NODA GA (i.e. 2,2′-(7-(1-carboxy-4-((4-isothiocyanate benzyl) amino)-4-oxobutyl)-1,4,7-triazonane-1,4-diyl) diacetic acid) in triethyl amine as an alkaline solvent, to obtain a 6-aminohexyl lactoside-NCS-benzyl-NODA GA conjugate. In this novel preparation method, no deglycosylated side product is produced, such that the yield is considerably increased to 46%. Therefore, the method is suitable for future massive production since the requirement for repeated preparations for massive production is reduced, and the impurities produced in the previously scaled-up preparation process are not present.